PCSK9 and Hypercholesterolemia: Also, considering drug availability, cost-effectiveness, safety, tolerability, and genotype, current therapeutic guidelines [56, 59, 60] for hypercholesterolemia that start with statins with additions of other LLTs and are followed by PCSK9 inhibitors are still relevant, including for those with HoFH or compound heterozygous.